Healthcare >> Analyst Interviews >> September 30, 2021
Broad Pullback in Biotech Provides Buying Opportunity for Specific Names
Matt Phipps, Ph.D., a biotechnology analyst, joined William Blair & Co, LLC, in November 2014, after working as a postdoctoral research fellow at Texas Scottish Rite Hospital for Children. In the 2019 StarMine Analyst Awards from Refinitiv, Dr. Phipps was ranked the No. 1 earnings estimator in biotechnology and No. 3 across all industries. Dr. Phipps earned a Ph.D. in cellular and molecular physiology from the University of Alabama at Birmingham and a B.S. in physics in medicine from the University of Notre Dame. Profile
Word count: 3,974
TWST: Tell us a little bit about yourself and what you find most interesting about the biopharma space?